Rizatriptan & Vestibular Migraine: Trial Results
- Rizatriptan, a common migraine medication, showed no notable benefit over a placebo in alleviating vertigo for adults experiencing vestibular migraine, according to a recent clinical trial.
- The double-blind, randomized trial, published in JAMA Neurology, examined the effectiveness of a 10 mg dose of rizatriptan in treating vestibular migraine attacks.
- The primary outcome measured the percentage of treated attacks where vertigo and unsteadiness/dizziness improved from moderate or severe to absent or mild after one hour.
rizatriptan,a common migraine treatment,offers no relief from vertigo for those with vestibular migraine,a new study confirms. The trial of 222 adults found the medication ineffective in easing dizziness and motion sensitivity within an hour. While a slight enhancement was observed at 24 hours, the findings advise against routine rizatriptan use for vestibular migraine attacks. Researchers sought to determine if the drug could alleviate the debilitating effects of this condition; however, results were disappointing. This details is just one finding you can find at News Directory 3, where we deliver breaking medical news. Discover what treatment advancements are on the horizon.
Rizatriptan Fails to Ease Vertigo in Vestibular Migraine Trial
Updated May 26, 2025
Rizatriptan, a common migraine medication, showed no notable benefit over a placebo in alleviating vertigo for adults experiencing vestibular migraine, according to a recent clinical trial. The study, conducted at two neurotologic centers from 2014 to 2020, involved 222 adults diagnosed with vestibular migraine; 71% were women, with an average age of 42.3 years.
The double-blind, randomized trial, published in JAMA Neurology, examined the effectiveness of a 10 mg dose of rizatriptan in treating vestibular migraine attacks. Participants were instructed to take the medication or placebo during up to three separate attacks. Researchers, led by Dr. Jeffrey P. Staab of the Mayo Clinic in Rochester, Minn., focused on whether the drug could alleviate vertigo and unsteadiness/dizziness within one hour.
The primary outcome measured the percentage of treated attacks where vertigo and unsteadiness/dizziness improved from moderate or severe to absent or mild after one hour. secondary outcomes included complete resolution of vestibular symptoms, headache relief, and any associated symptoms at one hour, as well as symptom alleviation at 24 hours, treatment satisfaction, and adverse effects at 48 hours. The analysis encompassed 240 attacks characterized by moderate to severe vestibular symptoms.
While rizatriptan did not outperform the placebo for vertigo or unsteadiness/dizziness at one hour, it did show some medium effects on unsteadiness/dizziness, photophobia or phonophobia, and motion sensitivity at 24 hours. Rescue medication use remained identical at 26.4% between both groups. Treatment satisfaction and quality-of-life outcomes at 48 hours yielded mixed results, and adverse events were similar across both groups.
“Results of this study do not support routine use of rizatriptan to treat vestibular migraine attacks,” the investigators wrote. “It was not efficacious for any symptoms at 1 hour and demonstrated no effects on vertigo.”
What’s next
Further research is needed to explore choice treatments for vestibular migraine,particularly in community and primary care settings,as this study focused on a specific subset of patients meeting strict diagnostic criteria at specialized centers.